Hepatitis C virus infection in the human immunodeficiency virus infected patient

Table 2 Treatment strategies including direct-acting antivirals in combination with ribavirin with or without pegylated interferon conducted in hepatitis C virus infected individuals with human immunodeficiency virus infection

Direct acting antiviral			Ribavirin/Peg Inf	Study name/ identifier1	Treatment duration	Phase	Primary endpoint	Presented results
Ns3/4a protease inhibitor	Ns5b polymerase inhibitors	Ns5a inhibitors
Boceprevir	No	No	Yes	NCT00959699	48 wk	APPROVED	SVR24	GT 1: 63%[123]
								Telaprevir	No	No	Yes	NCT00983853	48 wk	APPROVED	SVR12	GT 1: 74%[124]
Simeprevir	No	No	Yes	C212	24/48 wk2	III3	SVR12	GT 1: 79%-87%
				NCT01479868
Faldaprevir	No	No	Yes	Startverso4	24/48 wk2	III	SVR12	GT 1: 71%-72%
				NCT01399619

¹ClinicalTrials.gov;

²Simeprevir/faldaprevir+pegIFN/RBV for 12-24 wk, then pegIFN/RBV for 12-24 wk;

³Approved in HCV monoinfected with HCV genotype 1. RBV: Ribavirin; GT: Hepatitis C virus genotype; TN: Treatment naive; IFN: Interferon; TE: Treatment experienced; SVR: Sustained virological response; r: Ritonavir boosted.